1. G IN A lobal itiative for sthma lobal itiative for sthma

2. GINA Program Objectives  Increase appreciation of asthma as a global public health problem  Present key recommendations for diagnosis and management of asthma  Provide strategies to adapt recommendations to varying health needs, services, and resources  Identify areas for future investigation of particular significance to the global community  Increase appreciation of asthma as a global public health problem  Present key recommendations for diagnosis and management of asthma  Provide strategies to adapt recommendations to varying health needs, services, and resources  Identify areas for future investigation of particular significance to the global community

3. Executive Committee Chair: Paul O’Byrne, MD GINA Structure ScienceCommittee Chair: Eric Bateman, MD Dissemination/Implementation Task Group Chair: Wan Tan, MD

4. GINA Executive Committee P. O’Byrne, Chair, Canada E. Bateman, S. Africa S. Pedersen, Denmark J. Bousquet, France R. Singh, India T. Clark, UK M. Soto-Quiroz, Costa Rica K. Ohta, Japan W. Tan, Canada P. Paggario, Italy P. O’Byrne, Chair, Canada E. Bateman, S. Africa S. Pedersen, Denmark J. Bousquet, France R. Singh, India T. Clark, UK M. Soto-Quiroz, Costa Rica K. Ohta, Japan W. Tan, Canada P. Paggario, Italy

5. GINA Science Committee E. Bateman, Chair, S. Africa P. Barnes, UK K. Ohta, Japan J. Bousquet, France S. Pedersen, Denmark J. Drazen, US E. Pizzichini, Brazil M. FitzGerald, Canada S. Sullivan, US P. Gibson, Australia S. Wenzel, US P. O’Byrne, Canada H. Zar, S. Africa E. Bateman, Chair, S. Africa P. Barnes, UK K. Ohta, Japan J. Bousquet, France S. Pedersen, Denmark J. Drazen, US E. Pizzichini, Brazil M. FitzGerald, Canada S. Sullivan, US P. Gibson, Australia S. Wenzel, US P. O’Byrne, Canada H. Zar, S. Africa

6. Executive Committee Chair: Paul O’Byrne, MD GINA Structure ScienceCommittee Chair: Eric Bateman, MD Dissemination/Implementation Task Group Chair: Wan Tan, MD GINA ASSEMBLY

7. GINA Assembly n A network of individuals participating in the dissemination and implementation of asthma management programs at the local, national and regional level n GINA Assembly members are invited to meet with the GINA Executive Committee during the ATS and ERS meetings n A network of individuals participating in the dissemination and implementation of asthma management programs at the local, national and regional level n GINA Assembly members are invited to meet with the GINA Executive Committee during the ATS and ERS meetings

8. United States United Kingdom Argentina Australia Brazil Austria Canada Chile Belgium China Denmark Costa Rica Croatia Germany Greece Ireland Italy Syria Hong Kong ROC Japan India Korea Kyrgyzstan Moldova Macedonia Malta Netherlands New Zealand Poland Portugal Georgia Romania Russia Singapore Slovenia Saudi Arabia South Africa Spain Sweden Thailand Switzerland Ukraine Taiwan ROC Venezuela Vietnam Yugoslavia Albania Bangladesh France Mexico Turkey Czech Republic Lebanon Pakistan GINA Assembly Slovakia Guatemala

9. GINA Documents   Global Strategy for Asthma Management and Prevention (revised 2006)   Pocket Guide: Asthma Management and Prevention (revised 2006)   Pocket Guide: Asthma Management and Prevention in Children (revised 2006)   Guide for asthma patients and families All materials are available on GINA web site www.ginasthma.org   Global Strategy for Asthma Management and Prevention (revised 2006)   Pocket Guide: Asthma Management and Prevention (revised 2006)   Pocket Guide: Asthma Management and Prevention in Children (revised 2006)   Guide for asthma patients and families All materials are available on GINA web site www.ginasthma.org

10. Global Strategy for Asthma Management and Prevention  Evidence-based  Implementation oriented Diagnosis Management Prevention  Outcomes can be evaluated  Evidence-based  Implementation oriented Diagnosis Management Prevention  Outcomes can be evaluated

11. Global Strategy for Asthma Management and Prevention Evidence Category Sources of Evidence A Randomized clinical trials Rich body of data B Randomized clinical trials Limited body of data C Non-randomized trials Observational studies D Panel judgment consensus Evidence Category Sources of Evidence A Randomized clinical trials Rich body of data B Randomized clinical trials Limited body of data C Non-randomized trials Observational studies D Panel judgment consensus

12. Global Strategy for Asthma Management and Prevention (2006) Definition and Overview Diagnosis and Classification Asthma Medications Asthma Management and Prevention Program Implementation of Asthma Guidelines in Health Systems Definition and Overview Diagnosis and Classification Asthma Medications Asthma Management and Prevention Program Implementation of Asthma Guidelines in Health Systems Revised 2006

13. Definition of Asthma A chronic inflammatory disorder of the airways Many cells and cellular elements play a role Chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing Widespread, variable, and often reversible airflow limitation A chronic inflammatory disorder of the airways Many cells and cellular elements play a role Chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing Widespread, variable, and often reversible airflow limitation

14. Source: Peter J. Barnes, MD Asthma Inflammation: Cells and Mediators

15. Source: Peter J. Barnes, MD Mechanisms: Asthma Inflammation

16. Source: Peter J. Barnes, MD Asthma Inflammation: Cells and Mediators

17. Burden of Asthma Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence increasing in many countries, especially in children A major cause of school/work absence Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence increasing in many countries, especially in children A major cause of school/work absence

18. Burden of Asthma Health care expenditures very high Developed economies might expect to spend 1-2 percent of total health care expenditures on asthma. Developing economies likely to face increased demand Poorly controlled asthma is expensive; investment in prevention medication likely to yield cost savings in emergency care Health care expenditures very high Developed economies might expect to spend 1-2 percent of total health care expenditures on asthma. Developing economies likely to face increased demand Poorly controlled asthma is expensive; investment in prevention medication likely to yield cost savings in emergency care

19. Asthma Prevalence and Mortality Source: Masoli M et al. Allergy 2004

20. Countries should enter their own data on burden of asthma.

21. Risk Factors for Asthma Host factors: predispose individuals to, or protect them from, developing asthma Environmental factors: influence susceptibility to development of asthma in predisposed individuals, precipitate asthma exacerbations, and/or cause symptoms to persist Host factors: predispose individuals to, or protect them from, developing asthma Environmental factors: influence susceptibility to development of asthma in predisposed individuals, precipitate asthma exacerbations, and/or cause symptoms to persist

22. Factors that Exacerbate Asthma Allergens Respiratory infections Exercise and hyperventilation Weather changes Sulfur dioxide Food, additives, drugs

23. Factors that Influence Asthma Development and Expression Host Factors  Genetic - Atopy - Airway hyperresponsiveness  Gender  Obesity Host Factors  Genetic - Atopy - Airway hyperresponsiveness  Gender  Obesity Environmental Factors Indoor allergens Outdoor allergens Occupational sensitizers Tobacco smoke Air Pollution Respiratory Infections Diet Environmental Factors Indoor allergens Outdoor allergens Occupational sensitizers Tobacco smoke Air Pollution Respiratory Infections Diet

24. Is it Asthma? Recurrent episodes of wheezing Troublesome cough at night Cough or wheeze after exercise Cough, wheeze or chest tightness after exposure to airborne allergens or pollutants Colds “go to the chest” or take more than 10 days to clear

25. Asthma Diagnosis History and patterns of symptoms Measurements of lung function - Spirometry - Peak expiratory flow Measurement of airway responsiveness Measurements of allergic status to identify risk factors Extra measures may be required to diagnose asthma in children 5 years and younger and the elderly History and patterns of symptoms Measurements of lung function - Spirometry - Peak expiratory flow Measurement of airway responsiveness Measurements of allergic status to identify risk factors Extra measures may be required to diagnose asthma in children 5 years and younger and the elderly

26. Typical Spirometric (FEV 1 ) Tracings 1 Time (sec) 2345 FEV 1 Volume Normal Subject Asthmatic (After Bronchodilator) Asthmatic (Before Bronchodilator) Note: Each FEV 1 curve represents the highest of three repeat measurements

27. Measuring Variability of Peak Expiratory Flow

28. Measuring Airway Responsiveness

29. Clinical Control of Asthma   No (or minimal)* daytime symptoms   No limitations of activity   No nocturnal symptoms   No (or minimal) need for rescue medication   Normal lung function   No exacerbations _________ * Minimal = twice or less per week

30. Levels of Asthma Control Characteristic Controlled (All of the following) Partly controlled (Any present in any week) Uncontrolled Daytime symptoms None (2 or less / week) More than twice / week 3 or more features of partly controlled asthma present in any week Limitations of activities NoneAny Nocturnal symptoms / awakening NoneAny Need for rescue / “reliever” treatment None (2 or less / week) More than twice / week Lung function (PEF or FEV 1 ) Normal < 80% predicted or personal best (if known) on any day ExacerbationNone One or more / year 1 in any week

31. 1. Develop Patient/Doctor Partnership 2. Identify and Reduce Exposure to Risk Factors 3. Assess, Treat and Monitor Asthma 4. Manage Asthma Exacerbations 5. Special Considerations 1. Develop Patient/Doctor Partnership 2. Identify and Reduce Exposure to Risk Factors 3. Assess, Treat and Monitor Asthma 4. Manage Asthma Exacerbations 5. Special Considerations Asthma Management and Prevention Program: Five Components Asthma Management and Prevention Program: Five Components Revised 2006

32. Asthma Management and Prevention Program: Five Interrelated Components 1. Develop Patient/Doctor Partnership 2. Identify and Reduce Exposure to Risk Factors 3. Assess, Treat and Monitor Asthma 4. Manage Asthma Exacerbations 5. Special Considerations 1. Develop Patient/Doctor Partnership 2. Identify and Reduce Exposure to Risk Factors 3. Assess, Treat and Monitor Asthma 4. Manage Asthma Exacerbations 5. Special Considerations

33. Asthma Management and Prevention Program Goals of Long-term Management Achieve and maintain control of symptoms Maintain normal activity levels, including exercise Maintain pulmonary function as close to normal levels as possible Prevent asthma exacerbations Avoid adverse effects from asthma medications Prevent asthma mortality Achieve and maintain control of symptoms Maintain normal activity levels, including exercise Maintain pulmonary function as close to normal levels as possible Prevent asthma exacerbations Avoid adverse effects from asthma medications Prevent asthma mortality

34. Asthma Management and Prevention Program Asthma can be effectively controlled in most patients by intervening to suppress and reverse inflammation as well as treating bronchoconstriction and related symptoms Early intervention to stop exposure to the risk factors that sensitized the airway may help improve the control of asthma and reduce medication needs. Asthma can be effectively controlled in most patients by intervening to suppress and reverse inflammation as well as treating bronchoconstriction and related symptoms Early intervention to stop exposure to the risk factors that sensitized the airway may help improve the control of asthma and reduce medication needs..

35. Asthma Management and Prevention Program Although there is no cure for asthma, appropriate management that includes a partnership between the physician and the patient/family most often results in the achievement of control

36. Example Of Contents Of An Action Plan To Maintain Asthma Control Your Regular Treatment: 1. Each day take ___________________________ 2. Before exercise, take _____________________ WHEN TO INCREASE TREATMENT Assess your level of Asthma Control In the past week have you had: Daytime asthma symptoms more than 2 times ? NoYes Activity or exercise limited by asthma? NoYes Waking at night because of asthma? NoYes The need to use your [rescue medication] more than 2 times? No Yes If you are monitoring peak flow, peak flow less than________? NoYes If you answered YES to three or more of these questions, your asthma is uncontrolled and you may need to step up your treatment. HOW TO INCREASE TREATMENT STEP-UP your treatment as follows and assess improvement every day: ____________________________________________ [Write in next treatment step here] Maintain this treatment for _____________ days [specify number] WHEN TO CALL THE DOCTOR/CLINIC. Call your doctor/clinic: _______________ [provide phone numbers] If you don’t respond in _________ days [specify number] ______________________________ [optional lines for additional instruction] EMERGENCY/SEVERE LOSS OF CONTROL If you have severe shortness of breath, and can only speak in short sentences, If you are having a severe attack of asthma and are frightened, If you need your reliever medication more than every 4 hours and are not improving. 1. Take 2 to 4 puffs ___________ [reliever medication] 2. Take ____mg of ____________ [oral glucocorticosteroid] 3. Seek medical help: Go to _____________________; Address___________________ Phone: _______________________ 4. Continue to use your _________[reliever medication] until you are able to get medical help.

37. Asthma Management and Prevention Program Factors Involved in Non-Adherence Medication Usage Difficulties associated with inhalers Complicated regimens Fears about, or actual side effects Cost Distance to pharmacies Medication Usage Difficulties associated with inhalers Complicated regimens Fears about, or actual side effects Cost Distance to pharmacies Non-Medication Factors Misunderstanding/lack of information Fears about side-effects Inappropriate expectations Underestimation of severity Attitudes toward ill health Cultural factors Poor communication Non-Medication Factors Misunderstanding/lack of information Fears about side-effects Inappropriate expectations Underestimation of severity Attitudes toward ill health Cultural factors Poor communication

38. Asthma Management and Prevention Program Component 2: Identify and Reduce Exposure to Risk Factors Asthma Management and Prevention Program Component 2: Identify and Reduce Exposure to Risk Factors   Measures to prevent the development of asthma, and asthma exacerbations by avoiding or reducing exposure to risk factors should be implemented wherever possible.   Asthma exacerbations may be caused by a variety of risk factors – allergens, viral infections, pollutants and drugs.   Reducing exposure to some categories of risk factors improves the control of asthma and reduces medications needs.

39. Reduce exposure to indoor allergens Avoid tobacco smoke Avoid vehicle emission Identify irritants in the workplace Explore role of infections on asthma development, especially in children and young infants Asthma Management and Prevention Program Component 2: Identify and Reduce Exposure to Risk Factors Asthma Management and Prevention Program Component 2: Identify and Reduce Exposure to Risk Factors

40. Asthma Management and Prevention Program Influenza Vaccination Asthma Management and Prevention Program Influenza Vaccination   Influenza vaccination should be provided to patients with asthma when vaccination of the general population is advised   However, routine influenza vaccination of children and adults with asthma does not appear to protect them from asthma exacerbations or improve asthma control

41. A stepwise approach to pharmacological therapy is recommended The aim is to accomplish the goals of therapy with the least possible medication Although in many countries traditional methods of healing are used, their efficacy has not yet been established and their use can therefore not be recommended A stepwise approach to pharmacological therapy is recommended The aim is to accomplish the goals of therapy with the least possible medication Although in many countries traditional methods of healing are used, their efficacy has not yet been established and their use can therefore not be recommended Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma

42. Levels of Asthma Control CharacteristicControlled Partly controlled (Any present in any week) Uncontrolled Daytime symptoms None (2 or less / week) More than twice / week 3 or more features of partly controlled asthma present in any week Limitations of activities NoneAny Nocturnal symptoms / awakening NoneAny Need for rescue / “reliever” treatment None (2 or less / week) More than twice / week Lung function (PEF or FEV 1 ) Normal < 80% predicted or personal best (if known) on any day ExacerbationNone One or more / year 1 in any week

43. The choice of treatment should be guided by: Level of asthma control Current treatment Pharmacological properties and availability of the various forms of asthma treatment Economic considerations Cultural preferences and differing health care systems need to be considered The choice of treatment should be guided by: Level of asthma control Current treatment Pharmacological properties and availability of the various forms of asthma treatment Economic considerations Cultural preferences and differing health care systems need to be considered Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma

44. Component 4: Asthma Management and Prevention Program Controller Medications Component 4: Asthma Management and Prevention Program Controller Medications Inhaled glucocorticosteroids Leukotriene modifiers Long-acting inhaled β 2 -agonists Systemic glucocorticosteroids Theophylline Cromones Long-acting oral β 2 -agonists Anti-IgE Inhaled glucocorticosteroids Leukotriene modifiers Long-acting inhaled β 2 -agonists Systemic glucocorticosteroids Theophylline Cromones Long-acting oral β 2 -agonists Anti-IgE

45. Estimate Comparative Daily Dosages for Inhaled Glucocorticosteroids by Age Drug Low Daily Dose (  g) Medium Daily Dose (  g) High Daily Dose (  g) > 5 y Age 5 y Age 5 y Age < 5 y Drug Low Daily Dose (  g) Medium Daily Dose (  g) High Daily Dose (  g) > 5 y Age 5 y Age 5 y Age < 5 y Beclomethasone200-500 100-200 >500-1000 >200-400 >1000 >400 Budesonide200-600 100-200 600-1000 >200-400>1000 >400 Budesonide-Neb Inhalation Suspension 250-500 >500-1000 >1000 Ciclesonide 80 – 160 80-160 >160-320 >160-320>320-1280 >320 Flunisolide500-1000 500-750>1000-2000 >750-1250 >2000 >1250 Fluticasone100-250 100-200 >250-500 >200-500 >500 >500 Mometasone furoate200-400 100-200 > 400-800 >200-400>800-1200 >400 Triamcinolone acetonide400-1000 400-800>1000-2000 >800-1200>2000 >1200

46. Component 4: Asthma Management and Prevention Program Reliever Medications Component 4: Asthma Management and Prevention Program Reliever Medications   Rapid-acting inhaled β 2 -agonists   Systemic glucocorticosteroids   Anticholinergics   Theophylline   Short-acting oral β 2 -agonists   Rapid-acting inhaled β 2 -agonists   Systemic glucocorticosteroids   Anticholinergics   Theophylline   Short-acting oral β 2 -agonists

47. Component 4: Asthma Management and Prevention Program Allergen-specific Immunotherapy Greatest benefit of specific immunotherapy using allergen extracts has been obtained in the treatment of allergic rhinitis The role of specific immunotherapy in asthma is limited Specific immunotherapy should be considered only after strict environmental avoidance and pharmacologic intervention, including inhaled glucocorticosteroids, have failed to control asthma Perform only by trained physician Greatest benefit of specific immunotherapy using allergen extracts has been obtained in the treatment of allergic rhinitis The role of specific immunotherapy in asthma is limited Specific immunotherapy should be considered only after strict environmental avoidance and pharmacologic intervention, including inhaled glucocorticosteroids, have failed to control asthma Perform only by trained physician

48. controlled partly controlled uncontrolled exacerbation LEVEL OF CONTROL maintain and find lowest controlling step consider stepping up to gain control step up until controlled treat as exacerbation TREATMENT OF ACTION TREATMENT STEPS REDUCEINCREASE STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 REDUCE INCREASE

51. Step 1 – As-needed reliever medication   Patients with occasional daytime symptoms of short duration   A rapid-acting inhaled β 2 -agonist is the recommended reliever treatment (Evidence A)   When symptoms are more frequent, and/or worsen periodically, patients require regular controller treatment (step 2 or higher) Treating to Achieve Asthma Control

53. Step 2 – Reliever medication plus a single controller   A low-dose inhaled glucocorticosteroid is recommended as the initial controller treatment for patients of all ages (Evidence A)   Alternative controller medications include leukotriene modifiers (Evidence A) appropriate for patients unable/unwilling to use inhaled glucocorticosteroids Treating to Achieve Asthma Control

55. Step 3 – Reliever medication plus one or two controllers   For adults and adolescents, combine a low-dose inhaled glucocorticosteroid with an inhaled long- acting β 2 -agonist either in a combination inhaler device or as separate components (Evidence A)   Inhaled long-acting β 2 -agonist must not be used as monotherapy   For children, increase to a medium-dose inhaled glucocorticosteroid (Evidence A) Treating to Achieve Asthma Control

56. Additional Step 3 Options for Adolescents and Adults   Increase to medium-dose inhaled glucocorticosteroid (Evidence A)   Low-dose inhaled glucocorticosteroid combined with leukotriene modifiers (Evidence A)   Low-dose sustained-release theophylline (Evidence B) Treating to Achieve Asthma Control

58. Step 4 – Reliever medication plus two or more controllers   Selection of treatment at Step 4 depends on prior selections at Steps 2 and 3   Where possible, patients not controlled on Step 3 treatments should be referred to a health professional with expertise in the management of asthma Treating to Achieve Asthma Control

59. Step 4 – Reliever medication plus two or more controllers   Medium- or high-dose inhaled glucocorticosteroid combined with a long-acting inhaled β 2 -agonist (Evidence A)   Medium- or high-dose inhaled glucocorticosteroid combined with leukotriene modifiers (Evidence A)   Low-dose sustained-release theophylline added to medium- or high-dose inhaled glucocorticosteroid combined with a long-acting inhaled β 2 -agonist (Evidence B) Treating to Achieve Asthma Control

61. Step 5 – Reliever medication plus additional controller options   Addition of oral glucocorticosteroids to other controller medications may be effective (Evidence D) but is associated with severe side effects (Evidence A)   Addition of anti-IgE treatment to other controller medications improves control of allergic asthma when control has not been achieved on other medications (Evidence A)

62. Treating to Maintain Asthma Control   When control as been achieved, ongoing monitoring is essential to: - maintain control - establish lowest step/dose treatment   Asthma control should be monitored by the health care professional and by the patient

63. Treating to Maintain Asthma Control Stepping down treatment when asthma is controlled   When controlled on medium- to high-dose inhaled glucocorticosteroids: 50% dose reduction at 3 month intervals (Evidence B)   When controlled on low-dose inhaled glucocorticosteroids: switch to once-daily dosing (Evidence A)

64. Treating to Maintain Asthma Control Stepping down treatment when asthma is controlled   When controlled on combination inhaled glucocorticosteroids and long-acting inhaled β 2 -agonist, reduce dose of inhaled glucocorticosteroid by 50% while continuing the long-acting β 2 -agonist (Evidence B)   If control is maintained, reduce to low- dose inhaled glucocorticosteroids and stop long-acting β 2 -agonist (Evidence D)

65. Treating to Maintain Asthma Control Stepping up treatment in response to loss of control   Rapid-onset, short-acting or long- acting inhaled β2-agonist bronchodilators provide temporary relief.   Need for repeated dosing over more than one/two days signals need for possible increase in controller therapy

66. Childhood and adult asthma share the same underlying mechanisms. However, because of processes of growth and development, effects of asthma treatments in children differ from those in adults. Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma – Children 5 Years and Younger

67. Many asthma medications (e.g. glucocorticosteroids, β 2 - agonists, theophylline) are metabolized faster in children than in adults, and younger children tend to metabolize medications faster than older children Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma – Children 5 Years and Younger

68.  Long-term treatment with inhaled glucocorticosteroids has not been shown to be associated with any increase in osteoporosis or bone fracture  Studies including a total of over 3,500 children treated for periods of 1 – 13 years have found no sustained adverse effect of inhaled glucocorticosteroids on growth  Long-term treatment with inhaled glucocorticosteroids has not been shown to be associated with any increase in osteoporosis or bone fracture  Studies including a total of over 3,500 children treated for periods of 1 – 13 years have found no sustained adverse effect of inhaled glucocorticosteroids on growth Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma – Children 5 Years and Younger

69.  Rapid-acting inhaled β 2 -agonists are the most effective reliever therapy for children  These medications are the most effective bronchodilators available and are the treatment of choice for acute asthma symptoms  Rapid-acting inhaled β 2 -agonists are the most effective reliever therapy for children  These medications are the most effective bronchodilators available and are the treatment of choice for acute asthma symptoms Asthma Management and Prevention Program Component 3: Assess, Treat and Monitor Asthma – Children 5 Years and Younger

70.  Exacerbations of asthma are episodes of progressive increase in shortness of breath, cough, wheezing, or chest tightness  Exacerbations are characterized by decreases in expiratory airflow that can be quantified and monitored by measurement of lung function (FEV 1 or PEF)  Severe exacerbations are potentially life- threatening and treatment requires close supervision  Exacerbations of asthma are episodes of progressive increase in shortness of breath, cough, wheezing, or chest tightness  Exacerbations are characterized by decreases in expiratory airflow that can be quantified and monitored by measurement of lung function (FEV 1 or PEF)  Severe exacerbations are potentially life- threatening and treatment requires close supervision Asthma Management and Prevention Program Component 4: Manage Asthma Exacerbations

71. Treatment of exacerbations depends on:  The patient  Experience of the health care professional  Therapies that are the most effective for the particular patient  Availability of medications  Emergency facilities Treatment of exacerbations depends on:  The patient  Experience of the health care professional  Therapies that are the most effective for the particular patient  Availability of medications  Emergency facilities

72. Primary therapies for exacerbations: Repetitive administration of rapid-acting inhaled β 2 -agonist Early introduction of systemic glucocorticosteroids Oxygen supplementation Closely monitor response to treatment with serial measures of lung function Primary therapies for exacerbations: Repetitive administration of rapid-acting inhaled β 2 -agonist Early introduction of systemic glucocorticosteroids Oxygen supplementation Closely monitor response to treatment with serial measures of lung function Asthma Management and Prevention Program Component 4: Manage Asthma Exacerbations

73. Asthma Management and Prevention Program Asthma Management and Prevention Program Special Considerations Special considerations are required to manage asthma in relation to:  Pregnancy  Surgery  Rhinitis, sinusitis, and nasal polyps  Occupational asthma  Respiratory infections  Gastroesophageal reflux  Aspirin-induced asthma  Anaphylaxis and Asthma Special considerations are required to manage asthma in relation to:  Pregnancy  Surgery  Rhinitis, sinusitis, and nasal polyps  Occupational asthma  Respiratory infections  Gastroesophageal reflux  Aspirin-induced asthma  Anaphylaxis and Asthma

74. Asthma can be effectively controlled in most patients by intervening to suppress and reverse inflammation as well as treating bronchoconstriction and related symptoms Although there is no cure for asthma, appropriate management that includes a partnership between the physician and the patient/family most often results in the achievement of control Asthma can be effectively controlled in most patients by intervening to suppress and reverse inflammation as well as treating bronchoconstriction and related symptoms Although there is no cure for asthma, appropriate management that includes a partnership between the physician and the patient/family most often results in the achievement of control Asthma Management and Prevention Program: Summary

75.  A stepwise approach to pharmacologic therapy is recommended. The aim is to accomplish the goals of therapy with the least possible medication  The availability of varying forms of treatment, cultural preferences, and differing health care systems need to be considered  A stepwise approach to pharmacologic therapy is recommended. The aim is to accomplish the goals of therapy with the least possible medication  The availability of varying forms of treatment, cultural preferences, and differing health care systems need to be considered Asthma Management and Prevention Program: Summary

76. http://www.ginasthma.org

78. Alternate Slides for Asthma Treatment

79. CharacteristicControlled (All of the following) Partly Controlled (Any measure present in any week) Uncontrolled Daytime symptoms None (twice or less/week)More than twice/week Three or more features of partly controlled asthma present in any week Limitations of activities NoneAny Nocturnal symptoms/awakening NoneAny Need for reliever/ rescue treatment None (twice or less/week)More than twice/week Lung function (PEF or FEV 1 ) Normal< 80% predicted or personal best (if known) Exacerbations NoneOne or more/year*One in any week† Levels of Asthma Control * Any exacerbation should prompt review of maintenance treatment to ensure that it is adequate. † By definition, an exacerbation in any week makes that an uncontrolled asthma week.

84. Asthma Control: Treatment Steps Children Older than Five Years, Adolescents, Adults

85. Example Of Contents Of An Action Plan To Maintain Asthma Control Your Regular Treatment: 1. Each day take ___________________________ 2. Before exercise, take _____________________ WHEN TO INCREASE TREATMENT Assess your level of Asthma Control In the past week have you had: Daytime asthma symptoms more than 2 times ? NoYes Activity or exercise limited by asthma? NoYes Waking at night because of asthma? NoYes The need to use your [rescue medication] more than 2 times? No Yes If you are monitoring peak flow, peak flow less than________? NoYes If you answered YES to three or more of these questions, your asthma is uncontrolled and you may need to step up your treatment. HOW TO INCREASE TREATMENT STEP-UP your treatment as follows and assess improvement every day: ____________________________________________ [Write in next treatment step here] Maintain this treatment for _____________ days [specify number] WHEN TO CALL THE DOCTOR/CLINIC. Call your doctor/clinic: _______________ [provide phone numbers] If you don’t respond in _________ days [specify number] ______________________________ [optional lines for additional instruction] EMERGENCY/SEVERE LOSS OF CONTROL If you have severe shortness of breath, and can only speak in short sentences, If you are having a severe attack of asthma and are frightened, If you need your reliever medication more than every 4 hours and are not improving. 1. Take 2 to 4 puffs ___________ [reliever medication] 2. Take ____mg of ____________ [oral glucocorticosteroid] 3. Seek medical help: Go to _____________________; Address___________________ Phone: _______________________ 4. Continue to use your _________[reliever medication] until you are able to get medical help.